Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity.
Vander Mause ER, Baker JM, Dietze KA, Radhakrishnan SV, Iraguha T, Omili D, Davis P, Chidester SL, Modzelewska K, Panse J, Marvin JE, Olson ML, Steinbach M, Ng DP, Lim CS, Atanackovic D, Luetkens T. Vander Mause ER, et al. Among authors: radhakrishnan sv. Sci Transl Med. 2023 Jul 19;15(705):eadd7900. doi: 10.1126/scitranslmed.add7900. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467316
Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Atanackovic D, et al. Among authors: radhakrishnan sv. Br J Haematol. 2016 Mar;172(5):685-98. doi: 10.1111/bjh.13889. Epub 2016 Jan 20. Br J Haematol. 2016. PMID: 26791002 Free article. Review.
Immunotherapies targeting CD38 in Multiple Myeloma.
Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T. Atanackovic D, et al. Among authors: radhakrishnan sv. Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016. Oncoimmunology. 2016. PMID: 27999737 Free PMC article. Review.
Current Strategies for the Immunotherapy of Multiple Myeloma.
Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D. Luetkens T, et al. Among authors: radhakrishnan sv. Oncology (Williston Park). 2017 Jan 15;31(1):55-63. Oncology (Williston Park). 2017. PMID: 28090624 Free article. Review.
Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Radhakrishnan SV, et al. Hum Vaccin Immunother. 2017 Aug 3;13(8):1751-1757. doi: 10.1080/21645515.2017.1327487. Epub 2017 Jun 12. Hum Vaccin Immunother. 2017. PMID: 28604269 Free PMC article. Review.
The role of surface molecule CD229 in Multiple Myeloma.
Olson M, Radhakrishnan SV, Luetkens T, Atanackovic D. Olson M, et al. Among authors: radhakrishnan sv. Clin Immunol. 2019 Jul;204:69-73. doi: 10.1016/j.clim.2018.10.006. Epub 2018 Oct 13. Clin Immunol. 2019. PMID: 30326256 Review.
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.
Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T. Atanackovic D, et al. Among authors: radhakrishnan sv. Leukemia. 2020 Jan;34(1):317-321. doi: 10.1038/s41375-019-0536-3. Epub 2019 Aug 13. Leukemia. 2020. PMID: 31409922 Clinical Trial. No abstract available.
30 results